The map for everything retatrutide.
Track its path to FDA approval and find relevant weight-management and metabolic-health providers across the U.S. — before availability changes.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs
Find providers by state and market
One continuously updated status record for retatrutide's trials, FDA review, and availability — sourced and dated.
A structured database of 0 medical weight-management, obesity-medicine, and metabolic-health locations across 0 states — with telehealth, insurance, and new-patient status.
When a practice tells RetaMaps directly that it expects to offer retatrutide if approved, we mark it — nothing implied, nothing assumed.
Be first to know when availability changes
Get an email when retatrutide's regulatory or commercial status changes, segmented to your area. Informational only.